Inactive Instrument

Interpace Biosciences, Inc. Stock price Other OTC

Equities

IDXG

US46062X3035

Managed Healthcare

Sales 2021 41.31M Sales 2022 31.84M Capitalization 4.44M
Net income 2021 -14M Net income 2022 -22M EV / Sales 2021 1.01 x
Net Debt 2021 10.65M Net Debt 2022 11.26M EV / Sales 2022 0.49 x
P/E ratio 2021
-2.06 x
P/E ratio 2022
-0.2 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 72.25%
More Fundamentals * Assessed data
Dynamic Chart
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M MT
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee CI
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director CI
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P CI
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer CI
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023 CI
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M MT
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Principal Financial Officer CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 62 20-11-30
Director of Finance/CFO 32 19-05-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 75 22-01-31
Director/Board Member 71 15-12-31
Director/Board Member 77 04-08-31
More insiders
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The Company, through its Interpace Diagnostics, provides clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, which is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, which is a molecular version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT, which is for the diagnosis of thyroid cancer from thyroid nodules utilizing a sequencing assay; ThyraMIR v2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer, and RespriDX, which differentiates lung cancer of primary versus metastatic origin.
More about the company
  1. Stock
  2. Equities
  3. Stock Interpace Biosciences, Inc.
  4. Stock Interpace Biosciences, Inc. - Other OTC